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Purpose: To present light and electron microscopic as well as
immunohistochemical findings after corneal cross-linking (CXL).
Methods: Six keratoconus corneas after CXL, 12 keratoconus
corneas without CXL, and 7 normal corneas were examined by light
microscopy, indirect immunohistochemistry using antibodies against
proapoptotic BAX, antiapoptotic survivin, and BCL-2, and anti–
smooth muscle actin and, in part, by transmission electron microscopy.
Direct immunofluorescence with 496-diamidino-2-phenylindole was
performed to analyze keratocytes/area in the anterior, middle, poste-
rior, peripheral, and central corneal stroma.
Results: The period between CXL and keratoplasty ranged from 5 to
30 months. All keratoconus corneas showed the typical histological
changes. Increased proapoptotic BAX expression and/or antiapoptotic
survivin expression were noticed in keratocytes and endothelium in 2
keratoconus specimens after CXL. Smooth muscle actin was only
observed in subepithelial scar tissue of 2 keratoconus corneas without
CXL. Keratoconus corneas after CXL revealed a significant reduction
in keratocyte counts in the entire cornea (P = 0.003) compared with
keratoconus corneas without CXL and normal corneas. This difference
was because of a loss of keratocytes in the anterior (P = 0.014) and
middle (P = 0.024) corneal stroma. Keratocytes in CXL corneas were
reduced in the center (P = 0.028) and the periphery (P = 0.047).
Conclusions: CXL in human keratoconus can cause considerable
morphologic corneal changes up to 30 months postoperatively.
Especially noteworthy is a long-lasting, maybe permanent, keratocyte
loss in the anterior and middle corneal stroma involving the central
and peripheral cornea. As long-term corneal damage after CXL is of
genuine concern, particular care should be taken to perform this
procedure only in accordance with investigational protocols.
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Keratoconus is a noninflammatory ectasia of the cornea withdocumented changes in corneal epithelial basement mem-
brane structure1–3; in stromal collagen composition, distribu-
tion, and organization leading to lamellar and/or fibrillar
slippage2,4–7; in extracellular matrix components3; and in ker-
atocyte morphology and cell–matrix interactions.8–10
In addition, collagen loss, proteoglycan changes, and
the upregulation of degradative enzymes have been shown in
keratoconus and support the occurrence of additional bio-
chemical changes.11–14 Histopathologic studies of keratoconus
corneas reported fragmentation of the epithelial basement
membrane, superficial linear ruptures in Bowman layer filled
with fibrotic connective tissue, and folds in Descemet
membrane.15
Therapeutic options for patients with keratoconus include
rigid gas permeable contact lenses, intracorneal ring segments,
and topography-guided photorefractive keratectomy.16,17 In
approximately 20% of cases, keratoconus progresses to the
extent that corneal transplantation is unavoidable.18
In 2003, corneal cross-linking (CXL) using the photo-
sensitizer riboflavin and UVA light to increase the bio-
mechanical stability of the cornea and the resistance to
collagenases was shown to halt progression of keratoconus.19
In CXL-treated eyes, maximal keratometry readings and
refractive errors remained stable or decreased, whereas visual
acuity improved. Corneal transparency and endothelial cell
density remained unchanged by CXL.19 These findings in
keratoconus were confirmed by others,20–22 and the indication
for CXL was extended to corneal melting,23,24 keratitis refrac-
tive to therapy,25 and laser in situ keratomileusis–induced
keratectasia.26,27 Extrapolating from rabbit experiments, a
minimal corneal thickness of 400 mm was postulated also
in human CXL by Wollensak et al28,29 to prevent endothelial
damage.
In vivo confocal microscopic examination after CXL
showed a loss of keratocytes in the anterior and intermediate
stroma, associated with stromal edema immediately after
treatment. Gradual keratocyte repopulation of the corneal
stroma, starting between the second and third postoperative
month, becoming complete after 6 months, and continuing
thereafter was reported by Mazotta et al.30 Between the third
and the sixth months after CXL, increased density with hyper-
reflectivity of the extracellular matrix combined with
activated keratocyte nuclei and elongated cell processes was
seen. In late scans 2 years after the procedure, “bridge”- and
“needle-”shaped hyperreflective bands compatible with newly
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replaced collagen and different lamellar interconnections
were documented.31,32 This is in accordance with the histo-
logical findings in rabbit corneas after CXL, where repopulat-
ing keratocytes were observed to repair the cytotoxic effects
in 6-weeks time.33 Recently, histology of one normal human
cornea 24 hours after CXL was reported. It confirmed the
complete loss of keratocytes down to a depth of 250 to
280 mm with normal keratocyte densities beneath in the
immediate postoperative course.34 We report for the first time
histological, immunohistological, and electron microscopic
findings in 6 corneas treated with CXL 5 to 30 months before
keratoplasty and compare these findings with normal corneas
and keratoconic corneas without CXL treatment.
PATIENTS AND METHODS
All 6 CXL procedures were performed elsewhere, and
preoperative data were provided retrospectively by the cor-
responding surgeons. Clinical patients’ characteristics are
given in Table 1. CXL was performed using a standard
protocol with 0.1% riboflavin application every 2 minutes
for 60 minutes and concomitant UVA irradiation (370 nm;
3 mW/cm2) for the last 30 minutes in all patients. In 2 patients,
hypoosmolar riboflavin was added to increase corneal thick-
ness intraoperatively to a minimum of 400 mm. Additional
procedures were performed in 2 patients. One patient under-
went photorefractive keratectomy 21 months after CXL, and
a second CXL procedure was performed 4 months later
(patient 4). In a second patient, corneal ring implantation
was performed 12 months after CXL (patient 6). However,
a small corneal perforation intraoperatively necessitated the
immediate explantation of the ring segment. Corneal trans-
plantation was required in all 6 patients because of further
decrease in visual acuity associated with increased astigma-
tism and/or worsened corneal scarring 5 to 30 months after
CXL. For comparison, 12 keratoconic corneas without CXL
were obtained after keratoplasty for progressive disease. In
addition, 7 normal corneas were taken from eyes enucleated
for intraocular melanoma.
Specimens were fixed in 4% formaldehyde in 0.075 M
phosphate buffer for 24 hours, dehydrated in increasing
concentrations of ethanol (70%–99%), and infiltrated with
paraffin (Merck, Darmstadt, Germany) at 60°C. Sections with
a thickness of 3 mm were cut and floated on deionized water
at 45°C and mounted as single sections on Superfrost Plus
glass slides (Menzel-Gläser, Braunschweig, Germany). Slides
were subsequently dried at 60°C for 1 hour and stained with
hematoxylin and eosin, periodic-acid Schiff, and Alcian blue.
For immunohistochemistry, formalin-fixed corneal but-
tons were mounted on Super Frost Plus slides, deparaffinized
and steamed in target retrieval solution for 30 minutes. The
tissue was immunostained using the alkaline phosphatase–
antialkaline phosphatase method (APAAP). Primary antibod-
ies and dilutions used are listed in Table 2. Briefly, the primary
antibody was applied for 30 minutes. Thereafter, the tissue
was incubated with biotinylated secondary antibodies (Dako
ChemMate Detection Kit APAAP, Mouse) and APAAP com-
plex (Dako ChemMate Detection Kit APAAP) as a tertiary
reagent for 20 minutes each. The slides were developed
for 10 minutes in a solution of chromogen Fast Red substrate
(DakoCytomation, Hamburg, Germany). Tris-buffered normal
saline (pH 7.6) was used as wash buffer between steps and
as negative control. Antibody dilutions were made with ready-
made antibody diluent (DakoCytomation) for primary anti-
bodies. All slides were counterstained with hemalaun and
mounted in Malinol (Waldeck GmbH & Co Division Chroma,
Münster, Germany). Tissue from a conjunctival intraepithelial
carcinoma and a basal cell carcinoma was used as a positive
control.
For direct immunofluorescence, 3-mm unstained
sections were deparaffinized and immunostained with
496-diamidino-2-phenylindole (Vector Laboratories Ltd,
Peterborough, UK) as a nuclear stain to analyze keratocyte
densities. A JenOptic ProGress camera attached to a Leica
Fluorescence DM 2500 microscope was used to document
sections. Images were processed further with Adobe Photo-
shop CS5.1 to split corneal stromal images into 9 areas: 2
peripheral corneal sections, 1 central corneal section, anterior
corneal stroma, middle corneal stroma, and posterior corneal
stroma. Adobe Photoshop CS5.1 software was also used to
count keratocytes manually and analyze referring corneal
stromal areas to obtain keratocyte counts per area (1 mio
pixel).
Transmission Electron Microscopy
Tissue specimens of 3 keratoconus patients after CXL
were postfixed in 2% osmium tetroxide, processed through




















1 59 F 540 1/50 No No 6 ⇔ [
2 20 M 402 20/400 No No 9 Y [
3 15 M 461 20/50 Yes No 5 [ [
4 24 M n.k. n.k. n.k. PRK, 2CXL 30/23 [ [
5 34 M 557 20/100 No No 6 [ ⇔
6 53 M 344 20/40 Yes Corneal ring
implant
26 ⇔ [
2CXL, second crosslinking procedure; F, female; KP, keratoplasty; M, male; n.k., not known; PRK, photorefractive keratectomy; VA, visual acuity.
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alcohol and propylene oxide for embedding in Araldite or
acetone–Durcupan and sectioned with a Reichert-Jung ultra-
tome. Semithin sections were stained with toluidine blue,
whereas ultrathin sections were stained with uranyl acetate
and lead citrate and examined under a Zeiss transmission
electron microscope. Statistics were performed using x2 and
Kruskal–Wallis tests, as well as Spearman correlations. The
results were considered statistically significant at P , 0.05.
RESULTS
Histology
Histological findings in all keratoconus specimens after
CXL included thinning of the central corneal epithelium with
an intact epithelial basement membrane, breaks in Bowman
layer, a thinned (para-) central corneal stroma with reduction
of keratocytes, as well as an unaffected Descemet membrane
with an intact endothelium (Fig. 1). Collagen structure did not
differ between keratoconus with and without CXL by light
microscopy. In 1 cornea (patient 4), which had undergone
several surgical procedures, the Alcian blue stain revealed
deposits of acid mucopolysaccharides in the corneal stroma,
in keratocytes, and in endothelial cells.
Immunohistochemistry
BAX, Survivin, BCL-2
Proapoptotic BAX stained positive in the epithelium of
1 normal cornea, and in 8 of 12 keratoconus epithelia without
CXL. Corneal epithelium of keratoconus specimens after
CXL was negative for BAX. BAX did not stain the kerato-
cytes or the endothelium in any normal cornea or any
keratoconus cornea without CXL, but was positive in kerato-
cytes and endothelium in 2 keratoconus corneas after CXL
(Fig. 2A). Antiapoptotic survivin positivity was observed in
the epithelium of 4 keratoconus corneas without CXL, and in
1 keratoconus cornea with CXL. In addition, survivin expres-
sion was present in the endothelium of 1 keratoconus cornea
after CXL. In 1 normal cornea, antiapoptotic BCL-2 was
present in several keratocytes. All other corneas were nega-
tive for this marker.
Smooth Muscle Actin
Smooth muscle actin stained positive only in subepi-
thelial scar tissues of 2 keratoconus corneas without CXL
(Fig. 2B). Neither normal corneas nor keratoconus corneas
after CXL demonstrated any keratocytes positive for smooth
muscle actin keratocytes.
Transmission Electron Microscopy
Electron microscopy was performed in 3 keratoconus
specimens after CXL. It showed a compact collagenous
matrix containing few cellular elements in the anterior stroma
with thin vacuolated cytoplasmic processes: Moreover,
degenerative changes of keratocytes were observed in the
anterior stroma with loss of osmiophilic staining. The
posterior stroma and the endothelium seemed relatively
unremarkable, but an increased number of intracellular
vacuoles were present in posterior keratocytes and endothelial
cells.
Keratocyte Counts
Overall keratocyte counts per area were significantly
decreased in keratoconus corneas after CXL (P = 0.033)
FIGURE 1. A, Keratoconus cornea 6 months after CXL with
centrally thinned corneal epithelium, breaks in Bowman layer,
and thinned corneal stroma with near complete loss of kera-
tocytes. The endothelium seems normal (hematoxylin–eosin,
original magnification ·20). B, Keratoconus cornea 5 months
after CXL. The corneal stroma is thinned centrally with a sig-
nificant loss of keratocytes in the anterior stroma (hematoxylin–
eosin, original magnification ·20).
TABLE 2. Characteristics of Antibodies Used
Antibody Company Host Dilution
BAX DAKO Polyclonal rabbit 1:50
Survivin DAKO Monoclonal mouse 1:10
BCL-2 DAKO Monoclonal mouse 1:200
Smooth muscle actin DAKO Monoclonal mouse 1:100
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compared with normal corneas and keratoconus corneas with-
out CXL (Fig. 3). Keratocytes per 1 mio pixel were 328 (±81)
cells in normal corneas, 398 (±97) cells in keratoconus
corneas without CXL and 244 (±145) cells in keratoconus
corneas after CXL. This difference was especially obvious in
the anterior (P = 0.014) and middle (P = 0.024) corneal
stroma (Fig. 4). Keratocyte counts in the anterior stroma
averaged 399 (±119) in normal corneas, 378 (±96) in kerato-
conus without CXL, and 187 (±127) in keratoconus with
CXL. In the middle stroma, measurements were 347 (±74)
keratocytes for normal corneas, 426 (±123) keratocytes for
keratoconus corneas without CXL, and 274 (±213) kerato-
cytes for keratoconus after CXL. In the posterior stroma,
keratocyte counts were not significantly decreased in kerato-
conus corneas after CXL compared with normal corneas and
keratoconus corneas without CXL. Interestingly, keratocytes
were reduced after CXL in the peripheral (P = 0.047) and the
central corneal stroma (P = 0.028; Fig. 5). No correlation was
evident between keratocyte counts and time since CXL. CXL
corneas in which hypoosmolar riboflavin was used in addition
to swelling the corneal stroma did not show a significant
difference in keratocyte counts compared with corneas that
underwent CXL according to the standard protocol. The same
was true for corneas that underwent a second procedure
including photorefractive keratectomy, corneal ring implanta-
tion, or a second CXL.
DISCUSSION
CXL by combined riboflavin–UVA treatment was
introduced in 2003 as a promising new therapy in keratoconus
to stop progression and delay keratoplasty.19 Histological
changes in keratoconus patients after this procedure have
not been published. We observed long-term toxic effects of
CXL treatment in keratoconus corneas.
In cell culture experiments and rabbits, riboflavin–UVA
was shown to lead to dose-dependent apoptotic keratocyte
damage 24 hours postoperatively by the formation of reactive
oxygen species.33,35,36 According to Wollensak et al,35,36
keratocyte damage can be expected in human corneas down
to a depth of 300 mm using the standard surface UVA irra-
diance of 3 mW/cm2 (5.4 J/cm2). And indeed, complete loss of
keratocytes down to a depth of 250 to 280 mm with normal
keratocyte density beneath was shown in a normal human
cornea 24 hours after CXL.34 Endothelial necrosis and apopto-
sis occurred in rabbit cornea with a corneal thickness less than
400 mm.28 Therefore, a minimum corneal thickness of 400 mm
FIGURE 2. A, Keratoconus cornea after CXL. BAX-positive
keratocytes in the deep corneal stroma (asterisk) and BAX-
positive endothelial cells (arrow; original magnification ·40).
B, Smooth muscle actin–positive myofibroblasts in subepi-
thelial scar tissue of keratoconus cornea without CXL.
FIGURE 3. A, Keratoconus cornea without CXL. Normal dis-
tribution of keratocytes in the corneal stroma (DAPI stain,
original magnification ·10). B, Keratoconus cornea 6 months
after CXL. Near complete loss of keratocytes in the anterior
and middle stroma (DAPI stain, original magnification ·10).
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(without epithelium) was postulated to be safe in human CXL
treatment. Preoperative swelling of the cornea with hypoosmo-
lar riboflavin, however, has been shown to be effective and
safe in keratoconus patients with thinner corneas.37
Wound healing experiments in approximately 300 mm
thin rabbit corneas after CXL showed a complete loss of
endothelial cells and stromal keratocytes by day 3. On day
7, the endothelium was intact again, and keratocyte repopu-
lation of the posterior stroma began. By week 4, keratocyte
repopulation of the anterior stroma was observed, with
normal cytoarchitecture by week 6.33 In vivo confocal micros-
copy in humans after CXL also demonstrated a reduction in
anterior and intermediate stromal keratocytes followed by
a gradual repopulation until up to 6 months.30 In our study,
keratocyte loss was still evident 5 to 30 months after CXL in
keratoconus patients. The cell loss was mainly confined to the
anterior and middle stroma, but it involved the central and the
peripheral cornea. This finding is in complete disagreement to
animal studies and in vivo confocal studies in humans.
Additional procedures, such as photorefractive keratectomy,
corneal ring implantation, or a second CXL procedure were
not responsible for this keratocyte loss. In addition, the use
of hypoosmolar riboflavin to increase stromal thickness to
a minimum of 400 mm for treatment was not associated with
a further keratocyte reduction compared with patients treated
with the standard protocol.
We were surprised to find keratocytes and endothelial
cells staining for proapoptotic BAX and antiapoptotic survivin
in keratoconus specimens after CXL compared with normal
corneas and keratoconus corneas without CXL. The CXL
procedure itself does not seem to be responsible because these
markers are typically expressed only for a short time after
wounding. It may be a feature associated with keratoconus
itself, as Kaldawy et al8 could also demonstrate apoptotic cells
in all 3 layers of the keratoconus corneas. However, our kera-
toconus specimens without CXL did not express any apoptosis
markers in the stroma or endothelium. Thus, it may be specu-
lated that the CXL procedure may be indirectly involved. Fur-
ther research is certainly warranted to explain these findings.
Keratocyte apoptosis and necrosis are also known to
occur after mechanical epithelial debridement or incision
through the epithelium as performed as part of the CXL
procedure or in the case of keratoplasty. However, this
observation is only made in the anterior 50 mm of the corneal
stroma, is typically seen early after the trauma, and the
subsequent repopulation by activated stromal keratocytes
is complete in several days after the injury.38–42 In our study,
no difference was observed in keratocyte counts in the peri-
pheral cornea in keratoconus buttons without CXL and normal
corneas confirming that the trephine cut was not responsible
for the loss of keratocytes in the corneal periphery after CXL.
FIGURE 4. Mean keratocytes/area in anterior, middle, and
posterior corneal stroma in normal corneas, keratoconus
corneas without CXL, and keratoconus corneas after CXL.
A significant difference was evident between keratocyte
counts in keratoconus corneas with and without CXL in the
anterior (P = 0.05) and the middle stroma (P = 0.018). In
addition, significantly reduced keratocytes were present in the
anterior stroma of keratoconus corneas after CXL compared
with normal corneas (P = 0.014).
FIGURE 5. Mean keratocytes/area in the peripheral and central
corneal stroma in normal corneas, keratoconus corneas without
CXL, and keratoconus corneas after CXL. A significant reduction
of keratocytes was observed in keratoconus corneas after CXL in
the central (P = 0.018) and peripheral (P = 0.024) corneal
stroma compared with keratoconus corneas without CXL.
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Chronic keratocyte apoptosis associated with the ongo-
ing epithelial injury may be an important pathophysiological
factor in keratoconus mediated by interleukin-1 and Fas-
ligand.8,41,43 But keratocyte counts were not significantly dif-
ferent in keratoconus specimens without CXL and normal
corneas indicating that—indeed—CXL is responsible for
the keratocyte loss observed in our study.
Wollensak et al33 identified a-actin-positive myofibro-
blasts, especially in the periphery of the irradiated areas, by
weeks 4 and 6 after CXL in rabbit corneas. The presence of
these cells is interesting because myofibroblasts, presumed
derivatives of keratocytes responding to transforming growth
factor beta, are a critical component of the wound healing
cascade.44 They play a comprehensive role in collagen and
extracellular matrix remodeling through production of colla-
gen, glycosaminoglycans, collagenases, gelatinases, and
matrix metalloproteinases.45–47 The regression of keratectasia
in keratoconus patients after CXL might be explained in part
by the action of myofibroblasts.33 Five to 30 months after
CXL, we could not identify any actin-positive myofibroblasts
in the corneal stroma. The wound healing process after CXL
seems to be complete by that time. It may parallel wound
healing after photorefractive keratectomy, where myofibro-
blasts are typically observed for 3 months.47
The increase in biomechanical stiffness in corneas after
CXL is paralleled by an increase in corneal collagen diameter
in animal experiments.48 In vivo confocal microscopy con-
firmed an increased density of the anterior extracellular cor-
neal matrix starting between the third and sixth month
postoperatively with bridge-like and needle-shaped hyperre-
flective bands in humans after CXL.31 In our study, CXL
corneas did not show any obvious changes in collagen struc-
ture by light microscopy, but the anterior corneal stroma was
unusually compact by transmission electron microscopy.
Special measurements to document changes in collagen dia-
meter thickness were not performed.
Our results demonstrate that CXL can cause consider-
able long-term changes to keratoconus corneas. Our series of
cases having consisted of surgically removed corneas for
keratoconus is biased for poor outcome, but permanent
keratocyte loss after CXL is a potentially serious consequence
of the procedure that deserves further study. To exclude
additional negative influential factors, CXL treatment should
only be performed under investigational protocol.
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